54/120
2.3 / 5 stars
All 120 Win/Lose results shown below
ADMA Roast Me summary
ADMA BIOLOGICS, INC. (ADMA). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Win.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseADMA / S&P -7.10% / 15.20% |
LoseADMA / S&P 8.04% / 15.00% |
LoseADMA / S&P -18.60% / 50.40% |
| 2026-Q10/3 |
LoseADMA / S&P -50.60% / -4.33% |
LoseADMA / S&P 10.99% / 11.30% |
LoseADMA / S&P -20.00% / 27.70% |
| 2025-Q42/3 |
WinADMA / S&P 24.42% / 2.65% |
WinADMA / S&P 19.63% / 9.00% |
LoseADMA / S&P -25.93% / 13.40% |
| 2025-Q32/3 |
LoseADMA / S&P -19.49% / 8.12% |
WinADMA / S&P 27.62% / 4.61% |
WinADMA / S&P 207.14% / 13.45% |
| 2025-Q22/3 |
LoseADMA / S&P -8.22% / 10.94% |
WinADMA / S&P 43.58% / 4.83% |
WinADMA / S&P 514.29% / 10.63% |
| 2025-Q12/3 |
WinADMA / S&P 15.69% / -4.27% |
WinADMA / S&P 62.22% / 4.98% |
LoseADMA / S&P ADMA unavailable / 10.57% |
| 2024-Q41/3 |
LoseADMA / S&P -14.21% / 2.41% |
WinADMA / S&P 65.15% / 5.25% |
LoseADMA / S&P ADMA unavailable / 6.15% |
| 2024-Q32/3 |
WinADMA / S&P 78.80% / 5.89% |
WinADMA / S&P 63.39% / 5.89% |
LoseADMA / S&P ADMA unavailable / 6.11% |
| 2024-Q22/3 |
WinADMA / S&P 69.39% / 4.28% |
WinADMA / S&P 58.69% / 5.38% |
LoseADMA / S&P ADMA unavailable / 5.12% |
| 2024-Q12/3 |
WinADMA / S&P 46.02% / 10.56% |
WinADMA / S&P 55.69% / 5.71% |
LoseADMA / S&P ADMA unavailable / 5.59% |
| 2023-Q42/3 |
WinADMA / S&P 26.26% / 11.69% |
WinADMA / S&P 67.59% / 6.81% |
LoseADMA / S&P ADMA unavailable / 7.78% |
| 2023-Q32/3 |
WinADMA / S&P -2.98% / -3.27% |
WinADMA / S&P 79.56% / 7.52% |
LoseADMA / S&P ADMA unavailable / -5.03% |
| 2023-Q22/3 |
WinADMA / S&P 11.48% / 8.74% |
WinADMA / S&P 89.07% / 9.50% |
LoseADMA / S&P ADMA unavailable / -8.57% |
| 2023-Q11/3 |
LoseADMA / S&P -14.69% / 7.50% |
WinADMA / S&P 93.51% / 10.77% |
LoseADMA / S&P ADMA unavailable / -15.69% |
| 2022-Q42/3 |
WinADMA / S&P 59.67% / 7.56% |
WinADMA / S&P 90.36% / 11.88% |
LoseADMA / S&P ADMA unavailable / -17.99% |
| 2022-Q32/3 |
WinADMA / S&P 22.73% / -4.88% |
WinADMA / S&P 90.44% / 13.47% |
LoseADMA / S&P ADMA unavailable / -1.41% |
| 2022-Q22/3 |
WinADMA / S&P 8.20% / -16.10% |
WinADMA / S&P 89.41% / 13.71% |
LoseADMA / S&P ADMA unavailable / 11.04% |
| 2022-Q12/3 |
WinADMA / S&P 29.79% / -4.60% |
WinADMA / S&P 95.55% / 15.97% |
LoseADMA / S&P ADMA unavailable / 42.23% |
| 2021-Q42/3 |
WinADMA / S&P 24.78% / 11.03% |
WinADMA / S&P 91.72% / 15.00% |
LoseADMA / S&P ADMA unavailable / 96.40% |
| 2021-Q31/3 |
LoseADMA / S&P -29.38% / 0.58% |
WinADMA / S&P 70.01% / 10.77% |
LoseADMA / S&P ADMA unavailable / 69.42% |
| 2021-Q21/3 |
LoseADMA / S&P -9.09% / 8.55% |
WinADMA / S&P 56.02% / 6.58% |
LoseADMA / S&P ADMA unavailable / 51.81% |
| 2021-Q11/3 |
LoseADMA / S&P -9.74% / 6.17% |
WinADMA / S&P 33.45% / -1.06% |
LoseADMA / S&P ADMA unavailable / 7.39% |
| 2020-Q41/3 |
LoseADMA / S&P -18.41% / 12.15% |
WinADMA / S&P 43.85% / -3.72% |
LoseADMA / S&P ADMA unavailable / -33.42% |
| 2020-Q31/3 |
LoseADMA / S&P -18.43% / 8.93% |
WinADMA / S&P 88.60% / -2.04% |
LoseADMA / S&P ADMA unavailable / -27.10% |
| 2020-Q21/3 |
LoseADMA / S&P 1.74% / 20.54% |
WinADMA / S&P 102.69% / -0.46% |
LoseADMA / S&P ADMA unavailable / -27.11% |
| 2020-Q11/3 |
LoseADMA / S&P -28.00% / -19.60% |
WinADMA / S&P 118.68% / 3.47% |
LoseADMA / S&P ADMA unavailable / -14.75% |
| 2019-Q41/3 |
LoseADMA / S&P -10.11% / 9.07% |
WinADMA / S&P 72.79% / 5.36% |
LoseADMA / S&P ADMA unavailable / 2.99% |
| 2019-Q31/3 |
WinADMA / S&P 14.99% / 1.70% |
LoseADMA / S&P -14.29% / 5.02% |
LoseADMA / S&P ADMA unavailable / 0.21% |
| 2019-Q20/3 |
LoseADMA / S&P 2.11% / 4.30% |
LoseADMA / S&P -27.74% / 6.64% |
LoseADMA / S&P ADMA unavailable / 8.65% |
| 2019-Q11/3 |
WinADMA / S&P 58.58% / 13.65% |
LoseADMA / S&P -31.86% / 8.12% |
LoseADMA / S&P ADMA unavailable / 14.29% |
| 2018-Q40/3 |
LoseADMA / S&P -61.51% / -13.52% |
LoseADMA / S&P -25.37% / 9.05% |
LoseADMA / S&P ADMA unavailable / 18.23% |
| 2018-Q32/3 |
WinADMA / S&P 37.69% / 7.71% |
WinADMA / S&P 77.01% / 10.21% |
LoseADMA / S&P ADMA unavailable / 19.06% |
| 2018-Q21/3 |
LoseADMA / S&P -1.96% / 3.43% |
WinADMA / S&P 106.86% / 9.03% |
LoseADMA / S&P ADMA unavailable / 14.46% |
| 2018-Q12/3 |
WinADMA / S&P 43.30% / -0.76% |
WinADMA / S&P 116.49% / 7.68% |
LoseADMA / S&P ADMA unavailable / 12.46% |
| 2017-Q41/3 |
LoseADMA / S&P 4.22% / 6.64% |
WinADMA / S&P 113.49% / 7.03% |
LoseADMA / S&P ADMA unavailable / 13.82% |
| 2017-Q31/3 |
LoseADMA / S&P -16.76% / 4.48% |
WinADMA / S&P 43.06% / 5.68% |
LoseADMA / S&P ADMA unavailable / 17.57% |
| 2017-Q21/3 |
LoseADMA / S&P -24.18% / 3.09% |
WinADMA / S&P 40.34% / 4.83% |
LoseADMA / S&P ADMA unavailable / 17.74% |
| 2017-Q11/3 |
LoseADMA / S&P -4.69% / 6.07% |
WinADMA / S&P 43.18% / 3.67% |
LoseADMA / S&P ADMA unavailable / 13.32% |
| 2016-Q41/3 |
LoseADMA / S&P -29.28% / 3.82% |
WinADMA / S&P 48.53% / 2.09% |
LoseADMA / S&P ADMA unavailable / 7.05% |
| 2016-Q32/3 |
WinADMA / S&P 21.68% / 3.85% |
WinADMA / S&P 59.98% / 0.20% |
LoseADMA / S&P ADMA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | ADMA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -45.91% | 20.78% |
| Annualized return | -45.91% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | ADMA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 601.89% | 83.14% |
| Annualized return | 47.66% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | ADMA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 61.79% | 319.30% |
| Annualized return | 4.93% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |